Comparison between a GnRH agonist and a GnRH antagonist protocol for the same patient undergoing IVF

Abstract

In order to compare GnRH agonist with antagonist protocol for the same patient during controlled ovarian stimulation cycles, the in vitro fertilization and embryo transfer (IVF-ET) outcome was retrospectively studied in 81 patients undergoing 105 agonist protocols and 88 antagonist protocols. The results showed that there was no statistically significant difference in duration of ovarian stimulation, number of ampoules, oocytes retrieved, serum estradiol (E₂) and progesterone (P) levels, thickness of endometrium, the zygote-and blastocyst-development rate between GnRH agonist and antagonist protocols (P>0.05). High quality embryo rate was higher in antagonist protocols, but there was no significant difference between two protocols. Implantation rate and clinical pregnant rate were significantly higher in antagonist protocol (15.82% and 30.26%, respectively) than in agonist protocol (5.26% and 10.64% respectively (P<0.05). It was concluded GnRH antagonist protocol probably improved the outcome of pregnancy of older patients with a history of multiple failure of IVF-ET in a GnRH protocol.

Keywords

GnRH agonist / GnRH antagonist / in vitro fertilization and embryo transfer

References

[1] TarlatzisB. C., FauserB. C., KolibianakisE. M., et al.. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update, 2006, 12(4): 333-340

[2] PorterR. N., SmithW., CraftI. L., et al.. Induction of ovulation for in-vitro fertilization using buserelin and gonadotropins. Lancet, 1984, 2: 1284-1285

[3] KlingmullerD., SchepkeM., EnzweilerC., et al.. Hormonal responses to the new potent GnRH antagonist Cetrorelix. Acta Endocrinol (Copenh), 1993, 128: 15-18

[4] VarneyN. R., SyropC., KubuC. S., et al.. Neuropsychologic dysfunction in women following leuprolide acetate induction of hypoestrogenism. J Assist Reprod Genet, 1993, 10: 53-57

[5] Del GadilloJ. C., SiebzehnrüblE., DittrichR., et al.. Comparison of GnRH agonists and antagonists in unselected IVF/ICSI patients treated with different controlled ovarian hyperstimulation protocols: a matched study. Eur J Obstet Gynecol Reprod Biol, 2002, 102(2): 179-183

[6] XavierP., GamboaC., CalejoL., et al.. A randomized study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy. Eur J Obstet Gynecol Reprod Biol, 2005, 120(2): 185-189

[7] ElterK., NelsonL. R.. Use of third generation gonadotropin-releasing hormone antagonists in in vitro fertilization-embryo transfer: a review. Obstet Gynecol Surv, 2001, 56(9): 576-588

[8] AboulgharM. A., MansourR. T., SerourG. I., et al.. Increasing the dose of human menopausal gonadotropins on day of GnRH antagonist administration: randomized controlled trial.. Reprod Biomed Online, 2004, 8: 524-527

[9] MervielP., NajasS., CampyH., et al.. Use of GNRH antagonists in reproductive medicine. Minerva Ginecol, 2005, 57(1): 29-43

[10] TakahashiK., MukaidaT., TomiyamaT., et al.. GnRH antagonist improved blastocyst quality and pregnancy outcome after multiple failures of IVF/ICSI-ET with a GnRH agonist protocol. J Assist Reprod Genet, 2004, 21(9): 317-322

[11] FelberbaumR. E., DiedrichK.. Gonadotropin-releasing hormone antagonists: will they replace the agonists?. Reprod Biomed Online, 2002, 6: 43-53